Sanara MedTech (NASDAQ:SMTI - Get Free Report) is expected to be posting its quarterly earnings results before the market opens on Monday, March 24th. Analysts expect Sanara MedTech to post earnings of ($0.28) per share and revenue of $22.75 million for the quarter. Individual interested in registering for the company's earnings conference call can do so using this link.
Sanara MedTech Stock Performance
SMTI traded down $0.78 during midday trading on Thursday, reaching $33.87. The company's stock had a trading volume of 6,913 shares, compared to its average volume of 22,982. The stock has a market cap of $296.06 million, a P/E ratio of -34.27 and a beta of 1.37. The company has a fifty day simple moving average of $34.31 and a 200 day simple moving average of $33.86. The company has a current ratio of 2.23, a quick ratio of 2.02 and a debt-to-equity ratio of 0.76. Sanara MedTech has a twelve month low of $26.00 and a twelve month high of $39.08.
Analysts Set New Price Targets
SMTI has been the subject of a number of research reports. Cantor Fitzgerald reiterated an "overweight" rating and issued a $44.00 price objective on shares of Sanara MedTech in a research report on Wednesday, January 22nd. HC Wainwright reiterated a "buy" rating and issued a $50.00 price objective on shares of Sanara MedTech in a research report on Thursday, January 23rd.
Check Out Our Latest Research Report on SMTI
About Sanara MedTech
(
Get Free Report)
Sanara MedTech Inc, a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers.
Featured Articles
Before you consider Sanara MedTech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sanara MedTech wasn't on the list.
While Sanara MedTech currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
